Evidence map›Paper›PMID 27733634›Full record

Trial reportJournal of clinical microbiology2016

Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure.

A Jayakumar, R M Savic, C K Everett, D Benator, D Alland, C M Heilig, M Weiner, S O Friedrich, N A Martinson, A Kerrigan and 5 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. An Overview of Various Rifampicin Analogs againstMedicinal chemistry (Shariqah (United Arab Emirates)) · 2024
    Review
  3. Review
  4. Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

A JayakumarUniversity of California, San Francisco, Division of Pulmonary and Critical Care Medicine, San Francisco, California, USA.
R M SavicUniversity of California, San Francisco, School of Pharmacy, San Francisco, California, USA.
C K EverettUniversity of California, San Francisco, Division of Pulmonary and Critical Care Medicine, San Francisco, California, USA.
D BenatorWashington DC VA Medical Center and the George Washington University, Washington, DC, USA.
D AllandRutgers-New Jersey Medical School, Newark, New Jersey, USA.
C M HeiligDivision of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
M WeinerVeterans Administration Medical Center and University of Texas Health Science Center, San Antonio, Texas, USA.
S O FriedrichDivision of Medical Physiology, MRC Centre for Tuberculosis Research, DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
N A MartinsonPerinatal HIV Research Unit (PHRU), MRC Soweto Matlosana Collaborating Centre for HIV/AIDS and TB, University of the Witwatersrand, Johannesburg, South Africa.
A KerriganVanderbilt University School of Medicine, Nashville, Tennessee, USA.
C ZamudioUniversidad Peruana Cayetano Heredia, Lima, Peru.
S V GoldbergDivision of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
W C WhitworthDivision of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
J L DavisYale School of Public Health, New Haven, Connecticut, USA.
P NahidUniversity of California, San Francisco, Division of Pulmonary and Critical Care Medicine, San Francisco, California, USA pnahid@ucsf.edu.

Funding

MUTIDISCIPLINARY TRAINING PROGRAM IN LUNG DISEASEST32HL007185 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI David J Erle, LAURENCE HUANG · 1985 to 2026
$24.6M
TB Surrogate Markers for Assessing Reponse to Treatment (TB SMART Study)R01AI104589 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NAHID, PAYAM, SIGAL, GEORGE B · 2013 to 2017
$6.2M
Sputum M. tuberculosis DNA Kinetics During TB Treatment in Patients with HIVF32AI097005 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI EVERETT, CHARLES KNOX · 2011 to 2012
$144k
NHLBI NIH HHS T32 HL007185NIAID NIH HHS F32 AI097005NIAID NIH HHS R01 AI104589
6 · The paper itself

Abstract

The Xpert MTB/RIF assay is both sensitive and specific as a diagnostic test. Xpert also reports quantitative output in cycle threshold (C

Indexed as

AdolescentAdultDNA, BacterialFemaleHumansMaleMiddle AgedMycobacterium tuberculosisRifampinSensitivity and SpecificitySputumTuberculosis, PulmonaryYoung AdultDNA, BacterialRifampinrifapentine

Identifiers

PMID27733634
PMCPMC5121396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.